Using Focused Pharmacovigilance for Ensuring Patient Safety Against Antileishmanial Drugs in Bangladesh’s National Kala-Azar Elimination Programme

Infectious Diseases of Poverty - United Kingdom
doi 10.1186/s40249-018-0461-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Risk Factors for Indian Kala-Azar

American Journal of Tropical Medicine and Hygiene
MedicineVirologyParasitologyInfectious Diseases
2005English

Syntheses of Organic Antimony Compounds as Anti-Kala-Azar. Drugs. IV

Yakugaku Zasshi
PharmacologyPharmaceutical Science
1949English

Syntheses of Organic Antimony Compounds as Anti-Kala-Azar Drugs. V

Yakugaku Zasshi
PharmacologyPharmaceutical Science
1949English

Le Kala-Azar Au Portugal

Annales de Parasitologie Humaine et Comparée
1983English

Sternal Puncture in Kala-Azar

The Lancet
Medicine
1939English

Infantile Kala-Azar in Britain.

BMJ
1975English

Syntheses of Organic Antimony Compounds as Anti-Kala-Azar Drugs. VIII

Yakugaku Zasshi
PharmacologyPharmaceutical Science
1949English

Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis

ISRN Parasitology
2014English

Kala-Azar. A Handbook for Students and Practitioners

American Journal of Tropical Medicine and Hygiene
MedicineVirologyParasitologyInfectious Diseases
1929English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy